Physician profile
Eric E Johnson
NPI 1184610958
$8,872.21
in general payments reported to CMS, 2019-2025
35 companies · $881 in 2025
The $881 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $1,036 · 2021: $1,262 · 2022: $1,613 · 2023: $1,293 · 2024: $986 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.72 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,142.43 | 2019-2024 | Xarelto |
| Amgen INC. | $956.70 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $865.52 | 2019-2025 | Brilinta, Airsupra, Farxiga |
| Pfizer INC. | $780.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $754.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.68 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $606.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $555.76 | 2020-2024 | Nexletol |
| Boston Scientific Corporation | $278.19 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $271.55 | 2022-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $219.82 | 2019-2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $215.82 | 2021-2025 | |
| Abbott Laboratories | $192.21 | 2019-2025 | Aveir |
| Merck Sharp & Dohme LLC | $173.75 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $153.85 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $146.89 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Kiniksa Pharmaceuticals, Ltd. | $109.84 | 2022-2023 | Arcalyst |
| Medtronic, INC. | $104.94 | 2022 | |
| Eisai INC. | $74.94 | 2023 | |
| Phathom Pharmaceuticals, INC. | $73.20 | 2024-2025 | Voquezna |
| Kiniksa Pharmaceuticals International, Plc | $70.60 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $61.06 | 2024 | Opsumit |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.52 | 2022 | |
| Philips North America LLC | $49.69 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $48.71 | 2021 | |
| Exact Sciences Corporation | $41.86 | 2023-2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.78 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $39.66 | 2019 | |
| Gilead Sciences, INC. | $38.42 | 2019 | |
| Heartflow, INC. | $34.32 | 2023 | Ffrct |
| Lexicon Pharmaceuticals, INC. | $22.83 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $20.79 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Scpharmaceuticals INC. | $13.55 | 2023 | |
| Genzyme Corporation | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.